Outcomes at index therapy by index treatment subset by 1L IC
| Treatment group . | BR . | R-CHOP . | ||||||
|---|---|---|---|---|---|---|---|---|
| n . | % . | 2-year EFS (95% CI) . | 5-year OS (95% CI) . | n . | % . | 2-year EFS (95% CI) . | 5-year OS (95% CI) . | |
| All treatments | 92 | 100 | 20% (13-31) | 66% (56-79) | 128 | 100 | 26% (20-35) | 73% (66-82) |
| Anti-CD20 monotherapy | 8 | 9 | 31% (10-96) | 54% (26-100) | 10 | 8 | 40% (19-85) | 89% (71-100) |
| Bendamustine ± CD20 | 2 | 2 | 0% (NA to NA) | 100% (100-100) | 30 | 23 | 32% (19-54) | 72% (56-93) |
| CHOP ± CD20 | 44 | 48 | 15% (7-31) | 65% (51-83) | 2 | 2 | 50% (13-100) | 100% (100-100) |
| Intensive salvage therapy | 4 | 4 | 33% (7-100) | 100% (100-100) | 48 | 38 | 19% (10-34) | 61% (49-77) |
| Lenalidomide based | 10 | 11 | 50% (27-93) | 83% (58-100) | 9 | 7 | 22% (7-75) | 83% (58-100) |
| Nonsystemic | 3 | 3 | 50% (13-100) | 100% (100-100) | 4 | 3 | 50% (19-100) | 100% (100-100) |
| Other chemotherapy | 7 | 8 | 0% (NA to NA) | 36% (12-100) | 8 | 6 | 25% (8-83) | 100% (100-100) |
| Radioimmunotherapy | 3 | 3 | 33% (7-100) | 67% (30-100) | 9 | 7 | 33% (13-84) | 50% (25-100) |
| Targeted therapy | 11 | 12 | 9% (1-59) | 70% (42-100) | 8 | 6 | 12% (2-78) | 100% (100-100) |
| Treatment group . | BR . | R-CHOP . | ||||||
|---|---|---|---|---|---|---|---|---|
| n . | % . | 2-year EFS (95% CI) . | 5-year OS (95% CI) . | n . | % . | 2-year EFS (95% CI) . | 5-year OS (95% CI) . | |
| All treatments | 92 | 100 | 20% (13-31) | 66% (56-79) | 128 | 100 | 26% (20-35) | 73% (66-82) |
| Anti-CD20 monotherapy | 8 | 9 | 31% (10-96) | 54% (26-100) | 10 | 8 | 40% (19-85) | 89% (71-100) |
| Bendamustine ± CD20 | 2 | 2 | 0% (NA to NA) | 100% (100-100) | 30 | 23 | 32% (19-54) | 72% (56-93) |
| CHOP ± CD20 | 44 | 48 | 15% (7-31) | 65% (51-83) | 2 | 2 | 50% (13-100) | 100% (100-100) |
| Intensive salvage therapy | 4 | 4 | 33% (7-100) | 100% (100-100) | 48 | 38 | 19% (10-34) | 61% (49-77) |
| Lenalidomide based | 10 | 11 | 50% (27-93) | 83% (58-100) | 9 | 7 | 22% (7-75) | 83% (58-100) |
| Nonsystemic | 3 | 3 | 50% (13-100) | 100% (100-100) | 4 | 3 | 50% (19-100) | 100% (100-100) |
| Other chemotherapy | 7 | 8 | 0% (NA to NA) | 36% (12-100) | 8 | 6 | 25% (8-83) | 100% (100-100) |
| Radioimmunotherapy | 3 | 3 | 33% (7-100) | 67% (30-100) | 9 | 7 | 33% (13-84) | 50% (25-100) |
| Targeted therapy | 11 | 12 | 9% (1-59) | 70% (42-100) | 8 | 6 | 12% (2-78) | 100% (100-100) |
1L, first line; NA, not available.